Uroplasty (UPI) 1.22 $UPI
Europe Neuromodulation Devices Market 2015 by Procedure, and by Geography - Analysis & Forecast to 2019
M2 - Fri May 29, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sph6nd/europe) has announced the addition of the "Europe Neuromodulation Devices Market by Procedure, and by Geography - Analysis & Forecast to 2019" report to their offering. The European Neuromodulation market is estimated to grow at a CAGR of 13.6% from 2014 to 2019 In 2014, Germany commanded a larger share of around 27.2% of the European neuromodulation market, followed by France. Increasing incidences of peripheral nerve injuries and neurological disorders, technological developments in nerve repair, and favorable reimbursement policies are expected to drive the market growth in this region. However, lacks of surgeons and patient awareness have an adverse effect on the neuromodulation market. In this report, the European neuromodulation market is broadly classified on the basis of procedure type and modality. The procedure segment is classified into internal stimulation and external stimulation. Based on modalities, the neuromodulation market is categorized into spinal cord stimulation, deep brain stimulation, vagus, nerve stimulation, sacral nerve stimulation, gastric electric stimulation, transcutaneous electrical nerve stimulation (TENS), and transcranial magnetic stimulation (TMS). Geographically, the market is divided into six countries, namely Germany, France, the U.K., Italy, Spain, and the RoE. Germany commanded the largest share of 27.2% of the European neuromodulation market in 2014, followed by France. The market in Germany is estimated to grow at a CAGR of 13.9% during the forecast period. Neuromodulation is one of the largest and fastest-growing segments of the global medical devices market. The number of novel neuromodulation devices approved by the FDA grew 35% in 2007, promising new neuromodulation therapies for diverse disorders such as migraine, obesity, obsessive compulsive disorder, and depression. Advances in neuromodulation therapies are multi-disciplinary, requiring the close collaboration of neuroscientists, engineers, and clinicians to reach fruition. The report has profiled the leading players in this market along with their developments (new product launches and partnerships, agreements, collaborations, and joint ventures) over the past few years and strategies adopted by them to sustain and strengthen their position in the European neuromodulation market. Boston Scientific (U.S.), Cyberonics (U.S), Medtronic, Inc. (U.S.), Depuy Synthes (Johnson & Johnson) (U.S.), and St. Jude Medical Inc. (U.S.) are some of the key players engaged in this market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Europe Neuromodulation Market, By Procedure 6 Europe Neuromodulation Market, By Geography 7 Europe Neuromodulation Market: Competitive Landscape 8 Europe Neuromodulation Market: By Company - ANM Adaptive Neuromodulation GmbH - Biocontrol Medical, Ltd. - Boston Scientific Corporation - Cerbomed GmbH - Cyberonics, Inc. - Depuy Synthes - Medtronic, Inc. - St. Jude Medical - The Magstim Company Limited - Uroplasty, Inc. For more information visit http://www.researchandmarkets.com/research/sph6nd/europe
BSX: 22.97 (+0.31), JNJ: 117.38 (+0.92), MDT: 85.77 (+1.51), STJ: 78.49 (+0.82), UPI: 1.22 (-0.03), CYBX: 69.95 (+0.86)
Global Internal Neurostimulation Market 2015 - Analysis & Forecasts to 2019 for the $8.5 Billion Market
M2 - Tue May 19, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7fslq/internal) has announced the addition of the "Internal Neurostimulation Market, by Type (Spinal Cord Stimulation, Deep brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation), by Application (Parkinson's Disease, Chronic Pain), by Geography - Analysis & Forecasts to 2019" report to their offering. The global internal neurostimulation market was valued at $4,850.1 million in 2014, and is expected to reach $8,585.1 million by 2019, at a CAGR of 12.1% from 2014 to 2019 The North American internal neurostimulation market was valued at $2,513.0 million in 2014, and is expected to reach $4,186.1 million by 2019, at a CAGR of 10.7% during the forecast period. Internal neurostimulation involves a surgical implantation of electrodes at specific areas, either in the dura mater or deep inside the brain. Medical practitioners measure the invasiveness of any surgical procedure or therapeutic device, based on incision size, collateral tissue damage, and recovery period. Thus, minimally invasive technologies are surgical techniques that reduce the physical impact of a medical procedure. The use of internal neurostimulation (minimally invasive) devices reduces the length of hospital stay, post-surgical complications, and improves the quality of life. The long-term cost savings associated with the use of minimally invasive neurostimulation devices has contributed to the significant growth of the internal neurostimulation market. In addition to this, increasing neurostimulation research activities to treat diabetes, widespread awareness associated with the benefits of neurostimulation methods, and growing prevalence of neurological disorders have equally contributed to the overall growth of the global internal neurostimulation market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Internal Neurostimulation Market, By Type 6 Internal Neurostimulation Market, By Application 7 Internal Neurostimulation Market, By Geography 8 Internal Neurostimulation Market: Competitive Landscape 9 Internal Neurostimulation Market, By Company - Boston Scientific Corporation (U.S.) - Cyberonics, Inc. (U.S.) - Depuy Synthes Companies (U.S.) - Enteromedics, Inc. (U.S.) - Medtronic, Plc. (U.S.) - St. Jude Medical (U.S.) - Synapse Biomedical, Inc. (U.S.) - Uroplasty, Inc. (U.S.) For more information visit http://www.researchandmarkets.com/research/b7fslq/internal
BSX: 22.97 (+0.31), MDT: 85.77 (+1.51), STJ: 78.49 (+0.82), UPI: 1.22 (-0.03), CYBX: 69.95 (+0.86)
Cogentix Medical Reports Fourth Quarter and Full Year Fiscal 2015 Results
PR Newswire - Thu May 14, 3:01PM CDT
Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device company with innovative and proprietary products serving urology and airway management markets, today announced results for the fiscal fourth quarter and full year ended March 31, 2015.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03), CGNT: 1.09 (-0.01)
Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) - Forecast to 2019
M2 - Wed Apr 22, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2c5p7/asian_internal) has announced the addition of the "Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) -Forecast to 2019" report to their offering. The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of 13.8% between 2014 and 2019 Although the mature market of Japan holds the largest share in the internal neurostimulation/neuromodulation market, India is estimated to register the highest CAGR of 15.3% during the forecast period. The growth of the internal neurostimulation/neuromodulation market in Asia-Pacific is driven by public initiatives to increase awareness, technological developments, growing demand for the use of advanced technologies, and increasingly aging population. However, factors including lack of skilled professional and unfavorable reimbursement scenario are restraining the growth of this market. In this report, the Asia-Pacific internal neurostimulation/neuromodulation market has been broadly classified into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and gastric neurostimulator. The Spinal Cord Stimulator segment is further categorized by application into Chronic Pain, Failed Back Surgery Syndrome, Ischemic Pain and others. Likewise, Deep Brain Stimulation market has its application in Parkinson's Disease, Tremor, Depression, and others including Chronic Pain, Dystonia, Tourette's Syndrome, and Alzheimer's disease. Sacral Nerve Stimulation market has applications in Urinary Incontinence and Fecal Incontinence, while Vagus Nerve Stimulator comprises Epilepsy and other applications. Gastric Stimulation includes gastroparesis and others. The gastric neurostimulator market segment is estimated to register the highest CAGR between 2014 and 2019. The driver for this market is the increasing number of people suffering from severe GERD and gastroparesis. Most incidences of delayed bowel movement go unnoticed, which offers a significant growth opportunity for players in this segment. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Asia-Pacific Internal Neuromodulation/Neurostimulation Market: Macro Indicators, By Geography, 2014 ($ Bn) 4 Executive Summary 5 Market Overview 6 Internal Neurostimulation/Neuromodulation Market, By Modality 7 Internal Neurostimulation/Neuromodulation Market, By Application 8 Internal Neurostimulation/Neuromodulation Market, By Geography 9 Internal Neurostimulation/Neuromodulation Market: Competitive Landscape 10 Internal Neurostimulation/ Neuromodulation Market, By Company - Boston Scientific Corporation (U.S.) - Cerbomed Gmbh (Germany) - Cyberonics, Inc. (U.S.) - Depuy Synthes Companies (U.S.) - Enteromedics, Inc. (U.S.) - Medtronic, Inc. (U.S.) - St. Jude Medical (U.S.) - Synapse Biomedical, Inc. (U.S.) - Uroplasty, Inc. (U.S.) For more information visit http://www.researchandmarkets.com/research/c2...n_internal
BSX: 22.97 (+0.31), MDT: 85.77 (+1.51), STJ: 78.49 (+0.82), UPI: 1.22 (-0.03), CYBX: 69.95 (+0.86)
Uroplasty and Vision-Sciences Complete Merger
PR Newswire - Tue Mar 31, 3:00PM CDT
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) today announced the completion of their merger. The merger was originally announced in December 2014, and completion of the all-stock combination creates a new medical device company named Cogentix Medical, Inc. Beginning on April 1, 2015, Cogentix Medical, Inc. will trade on the NASDAQ under the symbol CGNT. Cogentix Medical will have its U.S. headquarters in Minnetonka, MN, where Uroplasty's current headquarters is located.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement
PR Newswire - Mon Mar 30, 10:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) shareholders have voted at the special meeting of each company's shareholders held today to approve the previously announced agreement and plan of merger between the two companies.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Uroplasty to Host Investor Meeting at Corporate Headquarters
PR Newswire - Tue Mar 03, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, will host a meeting for shareholders and analysts on Thursday, March 12, 2015, beginning at 3:00 pm Central Time, at Uroplasty's corporate headquarters in Minnetonka, Minnesota.
UPI: 1.22 (-0.03)
INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of Vision-Sciences, Inc. In Connection With the Fairness of the Merger of the Company to Uroplasty, Inc.
BusinessWire - Mon Feb 02, 2:57PM CST
Levi & Korsinsky is commencing an investigation into the Board of Directors of Vision-Sciences, Inc. ("Vision-Sciences" or "the Company"
(NasdaqCM:VSCI) in connection with possible breaches of fiduciary duty and other violations of state law in connection with the merger of the Company to Uroplasty, Inc. (NasdaqCM:UPI).
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 27, 5:09PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BLVD: 9.65 (-0.01), HTBX: 0.80 (+0.17), GLBZ: 10.79 (-0.01), LSCC: 5.84 (+0.20), SAL: 30.01 (+0.11), CRDS: 4.16 (-0.39), WVFC: 11.55 (+0.06), CRRC: 23.09 (-0.04), AMRB: 10.55 (+0.04), NFEC: 0.70 (unch), STAA: 5.62 (+0.36), SIMG: 7.30 (+0.02), SBSI: 31.28 (+1.12), UPI: 1.22 (-0.03), RITT: 0.27 (+0.01)
UPI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. - UPI
BusinessWire - Wed Dec 31, 11:33AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Uroplasty, Inc. (NasdaqCM:UPI) ("Uroplasty" in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM:VSCI).
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Europe Neuromodulation Devices Market 2015 by Procedure, and by Geography - Analysis & Forecast to 2019
M2 - Fri May 29, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sph6nd/europe) has announced the addition of the "Europe Neuromodulation Devices Market by Procedure, and by Geography - Analysis & Forecast to 2019" report to their offering. The European Neuromodulation market is estimated to grow at a CAGR of 13.6% from 2014 to 2019 In 2014, Germany commanded a larger share of around 27.2% of the European neuromodulation market, followed by France. Increasing incidences of peripheral nerve injuries and neurological disorders, technological developments in nerve repair, and favorable reimbursement policies are expected to drive the market growth in this region. However, lacks of surgeons and patient awareness have an adverse effect on the neuromodulation market. In this report, the European neuromodulation market is broadly classified on the basis of procedure type and modality. The procedure segment is classified into internal stimulation and external stimulation. Based on modalities, the neuromodulation market is categorized into spinal cord stimulation, deep brain stimulation, vagus, nerve stimulation, sacral nerve stimulation, gastric electric stimulation, transcutaneous electrical nerve stimulation (TENS), and transcranial magnetic stimulation (TMS). Geographically, the market is divided into six countries, namely Germany, France, the U.K., Italy, Spain, and the RoE. Germany commanded the largest share of 27.2% of the European neuromodulation market in 2014, followed by France. The market in Germany is estimated to grow at a CAGR of 13.9% during the forecast period. Neuromodulation is one of the largest and fastest-growing segments of the global medical devices market. The number of novel neuromodulation devices approved by the FDA grew 35% in 2007, promising new neuromodulation therapies for diverse disorders such as migraine, obesity, obsessive compulsive disorder, and depression. Advances in neuromodulation therapies are multi-disciplinary, requiring the close collaboration of neuroscientists, engineers, and clinicians to reach fruition. The report has profiled the leading players in this market along with their developments (new product launches and partnerships, agreements, collaborations, and joint ventures) over the past few years and strategies adopted by them to sustain and strengthen their position in the European neuromodulation market. Boston Scientific (U.S.), Cyberonics (U.S), Medtronic, Inc. (U.S.), Depuy Synthes (Johnson & Johnson) (U.S.), and St. Jude Medical Inc. (U.S.) are some of the key players engaged in this market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Europe Neuromodulation Market, By Procedure 6 Europe Neuromodulation Market, By Geography 7 Europe Neuromodulation Market: Competitive Landscape 8 Europe Neuromodulation Market: By Company - ANM Adaptive Neuromodulation GmbH - Biocontrol Medical, Ltd. - Boston Scientific Corporation - Cerbomed GmbH - Cyberonics, Inc. - Depuy Synthes - Medtronic, Inc. - St. Jude Medical - The Magstim Company Limited - Uroplasty, Inc. For more information visit http://www.researchandmarkets.com/research/sph6nd/europe
BSX: 22.97 (+0.31), JNJ: 117.38 (+0.92), MDT: 85.77 (+1.51), STJ: 78.49 (+0.82), UPI: 1.22 (-0.03), CYBX: 69.95 (+0.86)
Global Internal Neurostimulation Market 2015 - Analysis & Forecasts to 2019 for the $8.5 Billion Market
M2 - Tue May 19, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7fslq/internal) has announced the addition of the "Internal Neurostimulation Market, by Type (Spinal Cord Stimulation, Deep brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation), by Application (Parkinson's Disease, Chronic Pain), by Geography - Analysis & Forecasts to 2019" report to their offering. The global internal neurostimulation market was valued at $4,850.1 million in 2014, and is expected to reach $8,585.1 million by 2019, at a CAGR of 12.1% from 2014 to 2019 The North American internal neurostimulation market was valued at $2,513.0 million in 2014, and is expected to reach $4,186.1 million by 2019, at a CAGR of 10.7% during the forecast period. Internal neurostimulation involves a surgical implantation of electrodes at specific areas, either in the dura mater or deep inside the brain. Medical practitioners measure the invasiveness of any surgical procedure or therapeutic device, based on incision size, collateral tissue damage, and recovery period. Thus, minimally invasive technologies are surgical techniques that reduce the physical impact of a medical procedure. The use of internal neurostimulation (minimally invasive) devices reduces the length of hospital stay, post-surgical complications, and improves the quality of life. The long-term cost savings associated with the use of minimally invasive neurostimulation devices has contributed to the significant growth of the internal neurostimulation market. In addition to this, increasing neurostimulation research activities to treat diabetes, widespread awareness associated with the benefits of neurostimulation methods, and growing prevalence of neurological disorders have equally contributed to the overall growth of the global internal neurostimulation market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Internal Neurostimulation Market, By Type 6 Internal Neurostimulation Market, By Application 7 Internal Neurostimulation Market, By Geography 8 Internal Neurostimulation Market: Competitive Landscape 9 Internal Neurostimulation Market, By Company - Boston Scientific Corporation (U.S.) - Cyberonics, Inc. (U.S.) - Depuy Synthes Companies (U.S.) - Enteromedics, Inc. (U.S.) - Medtronic, Plc. (U.S.) - St. Jude Medical (U.S.) - Synapse Biomedical, Inc. (U.S.) - Uroplasty, Inc. (U.S.) For more information visit http://www.researchandmarkets.com/research/b7fslq/internal
BSX: 22.97 (+0.31), MDT: 85.77 (+1.51), STJ: 78.49 (+0.82), UPI: 1.22 (-0.03), CYBX: 69.95 (+0.86)
Cogentix Medical Reports Fourth Quarter and Full Year Fiscal 2015 Results
PR Newswire - Thu May 14, 3:01PM CDT
Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device company with innovative and proprietary products serving urology and airway management markets, today announced results for the fiscal fourth quarter and full year ended March 31, 2015.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03), CGNT: 1.09 (-0.01)
Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) - Forecast to 2019
M2 - Wed Apr 22, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c2c5p7/asian_internal) has announced the addition of the "Asian Internal Neurostimulation/Neuromodulation Market, by Modality (Spinal Cord Stimulator, Deep Brain Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Gastric Neurostimulator) -Forecast to 2019" report to their offering. The Asia-Pacific internal neurostimulation/neuromodulation market is estimated to register a CAGR of 13.8% between 2014 and 2019 Although the mature market of Japan holds the largest share in the internal neurostimulation/neuromodulation market, India is estimated to register the highest CAGR of 15.3% during the forecast period. The growth of the internal neurostimulation/neuromodulation market in Asia-Pacific is driven by public initiatives to increase awareness, technological developments, growing demand for the use of advanced technologies, and increasingly aging population. However, factors including lack of skilled professional and unfavorable reimbursement scenario are restraining the growth of this market. In this report, the Asia-Pacific internal neurostimulation/neuromodulation market has been broadly classified into spinal cord stimulator, deep brain stimulator, sacral nerve stimulator, vagus nerve stimulator, and gastric neurostimulator. The Spinal Cord Stimulator segment is further categorized by application into Chronic Pain, Failed Back Surgery Syndrome, Ischemic Pain and others. Likewise, Deep Brain Stimulation market has its application in Parkinson's Disease, Tremor, Depression, and others including Chronic Pain, Dystonia, Tourette's Syndrome, and Alzheimer's disease. Sacral Nerve Stimulation market has applications in Urinary Incontinence and Fecal Incontinence, while Vagus Nerve Stimulator comprises Epilepsy and other applications. Gastric Stimulation includes gastroparesis and others. The gastric neurostimulator market segment is estimated to register the highest CAGR between 2014 and 2019. The driver for this market is the increasing number of people suffering from severe GERD and gastroparesis. Most incidences of delayed bowel movement go unnoticed, which offers a significant growth opportunity for players in this segment. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Asia-Pacific Internal Neuromodulation/Neurostimulation Market: Macro Indicators, By Geography, 2014 ($ Bn) 4 Executive Summary 5 Market Overview 6 Internal Neurostimulation/Neuromodulation Market, By Modality 7 Internal Neurostimulation/Neuromodulation Market, By Application 8 Internal Neurostimulation/Neuromodulation Market, By Geography 9 Internal Neurostimulation/Neuromodulation Market: Competitive Landscape 10 Internal Neurostimulation/ Neuromodulation Market, By Company - Boston Scientific Corporation (U.S.) - Cerbomed Gmbh (Germany) - Cyberonics, Inc. (U.S.) - Depuy Synthes Companies (U.S.) - Enteromedics, Inc. (U.S.) - Medtronic, Inc. (U.S.) - St. Jude Medical (U.S.) - Synapse Biomedical, Inc. (U.S.) - Uroplasty, Inc. (U.S.) For more information visit http://www.researchandmarkets.com/research/c2...n_internal
BSX: 22.97 (+0.31), MDT: 85.77 (+1.51), STJ: 78.49 (+0.82), UPI: 1.22 (-0.03), CYBX: 69.95 (+0.86)
Uroplasty and Vision-Sciences Complete Merger
PR Newswire - Tue Mar 31, 3:00PM CDT
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) today announced the completion of their merger. The merger was originally announced in December 2014, and completion of the all-stock combination creates a new medical device company named Cogentix Medical, Inc. Beginning on April 1, 2015, Cogentix Medical, Inc. will trade on the NASDAQ under the symbol CGNT. Cogentix Medical will have its U.S. headquarters in Minnetonka, MN, where Uroplasty's current headquarters is located.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement
PR Newswire - Mon Mar 30, 10:00AM CDT
Uroplasty, Inc. (NASDAQ: UPI) and Vision-Sciences, Inc. (NASDAQ: VSCI) shareholders have voted at the special meeting of each company's shareholders held today to approve the previously announced agreement and plan of merger between the two companies.
VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Uroplasty to Host Investor Meeting at Corporate Headquarters
PR Newswire - Tue Mar 03, 6:00AM CST
Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, will host a meeting for shareholders and analysts on Thursday, March 12, 2015, beginning at 3:00 pm Central Time, at Uroplasty's corporate headquarters in Minnetonka, Minnesota.
UPI: 1.22 (-0.03)
INVESTOR ALERT: Levi & Korsinsky, LLP Commences an Investigation of the Board of Directors of Vision-Sciences, Inc. In Connection With the Fairness of the Merger of the Company to Uroplasty, Inc.
BusinessWire - Mon Feb 02, 2:57PM CST
Levi & Korsinsky is commencing an investigation into the Board of Directors of Vision-Sciences, Inc. ("Vision-Sciences" or "the Company"
(NasdaqCM:VSCI) in connection with possible breaches of fiduciary duty and other violations of state law in connection with the merger of the Company to Uroplasty, Inc. (NasdaqCM:UPI). VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 27, 5:09PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BLVD: 9.65 (-0.01), HTBX: 0.80 (+0.17), GLBZ: 10.79 (-0.01), LSCC: 5.84 (+0.20), SAL: 30.01 (+0.11), CRDS: 4.16 (-0.39), WVFC: 11.55 (+0.06), CRRC: 23.09 (-0.04), AMRB: 10.55 (+0.04), NFEC: 0.70 (unch), STAA: 5.62 (+0.36), SIMG: 7.30 (+0.02), SBSI: 31.28 (+1.12), UPI: 1.22 (-0.03), RITT: 0.27 (+0.01)
UPI SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Uroplasty, Inc. Regarding the Fairness of the Sale of the Company to Vision-Sciences, Inc. - UPI
BusinessWire - Wed Dec 31, 11:33AM CST
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Uroplasty, Inc. (NasdaqCM:UPI) ("Uroplasty"
in connection with the sale of the Company to Vision-Sciences, Inc. (NasdaqCM:VSCI). VSCI: 0.35 (-0.02), UPI: 1.22 (-0.03)
